Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells

English version České info

The immune system in the gastrointestinal tract plays a crucial role in the control of infection, as it constitutes the first line of defense against mucosal pathogens. The attractive features of oral immunization have led to the exploration of a variety of oral delivery systems. However, none of these oral delivery systems have been applied to existing commercial vaccines. To overcome this, a new generation of oral vaccine delivery systems that target antigens to gut-associated lymphoid tissue is required. One promising approach is to exploit the potential of microfold (M) cells by mimicking the entry of pathogens into these cells. Targeting specific receptors on the apical surface of M cells might enhance the entry of antigens, initiating the immune response and consequently leading to protection against mucosal pathogens. In this article, we briefly review the challenges associated with current oral vaccine delivery systems and discuss strategies that might potentially target mouse and human intestinal M cells.

Vyšlo v časopise: Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells. PLoS Pathog 6(11): e32767. doi:10.1371/journal.ppat.1001147
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001147

Souhrn

Zdroje

1. McGheeJR

MesteckyJ

DertzbaughMT

EldridgeJH

HirasawaM

1992

The mucosal immune system: from fundamental concepts to vaccine development.

Vaccine

2. McGheeJR

KiyonoH

1992

Mucosal immunity to vaccines: current concepts for vaccine development and immune response analysis.

Adv Exp Med Biol

327

3. Xu-AmanoJ

BeagleyKW

MegaJ

FujihashiK

KiyonoH

1992

Induction of T helper cells and cytokines for mucosal IgA responses.

Adv Exp Med Biol

327

107

117

4. MesteckyJ

1987

The common mucosal immune system and current strategies for induction of immune responses in external secretions.

J Clin Immunol

265

276

5. AziziA

GhunaimH

Diaz-MitomaF

MesteckyJ

2010

Mucosal HIV vaccines: a holy grail or a dud?

Vaccine

4015

4026

6. ParrEL

ParrMB

1990

A comparison of antibody titres in mouse uterine fluid after immunization by several routes, and the effect of the uterus on antibody titres in vaginal fluid.

J Reprod Fertil

619

625

7. HanebergB

KendallD

AmerongenHM

ApterFM

KraehenbuhlJP

1994

Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces.

Infect Immun

8. KozlowskiPA

Cu-UvinS

NeutraMR

FlaniganTP

1997

Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women.

Infect Immun

1387

1394

9. SentmanCL

MeadowsSK

WiraCR

ErikssonM

2004

Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone.

J Immunol

173

6760

6766

10. WiraCR

RossollRM

2003

Oestradiol regulation of antigen presentation by uterine stromal cells: role of transforming growth factor-beta production by epithelial cells in mediating antigen-presenting cell function.

Immunology

109

398

406

11. LuFX

MaZ

RourkeT

SrinivasanS

McChesneyM

1999

Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle.

Infect Immun

6321

6328

12. MesteckyJ

MoldoveanuZ

RussellMW

2005

Immunologic uniqueness of the genital tract: challenge for vaccine development.

Am J Reprod Immunol

208

214

13. HolmgrenJ

CzerkinskyC

2005

Mucosal immunity and vaccines.

Nat Med

S45

S53

14. LagranderieM

WinterN

BalazucAM

GicquelB

GheorghiuM

1998

A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes.

AIDS Res Hum Retroviruses

1625

1633

15. BergquistC

JohanssonEL

LagergardT

HolmgrenJ

RudinA

1997

Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.

Infect Immun

2676

2684

16. DurraniZ

McInerneyTL

McLainL

JonesT

BellabyT

1998

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.

J Immunol Methods

220

103

17. HirabayashiY

KurataH

FunatoH

NagamineT

AizawaC

1990

Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.

Vaccine

243

248

18. NarayanKM

DelRC

2010

Comparative efficacy of influenza vaccines.

N Engl J Med

362

179

180

19. FioreAE

BridgesCB

CoxNJ

2009

Seasonal influenza vaccines.

Curr Top Microbiol Immunol

333

20. MiyakeA

AkagiT

EnoseY

UenoM

KawamuraM

2004

Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.

J Med Virol

368

377

21. StoweJ

AndrewsN

WiseL

MillerE

2006

Bell's palsy and parenteral inactivated influenza vaccine.

Hum Vaccin

110

112

22. LewisDJ

HuoZ

BarnettS

KromannI

GiemzaR

2009

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.

PLoS ONE

e6999

doi:10.1371/journal.pone.0006999

23. MutschM

ZhouW

RhodesP

BoppM

ChenRT

2004

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.

N Engl J Med

350

896

903

24. BaumannU

2008

Mucosal vaccination against bacterial respiratory infections.

Expert Rev Vaccines

1257

1276

25. BrangerCG

Torres-EscobarA

SunW

PerryR

FetherstonJ

2009

Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonellaenterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.

Vaccine

5363

5370

26. FooksAR

2000

Development of oral vaccines for human use.

Curr Opin Mol Ther

27. KostrzakA

CervantesGM

GuetardD

NagarajuDB

Wain-HobsonS

2009

Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells.

Vaccine

4798

4807

28. GrdicD

SmithR

DonachieA

KjerrulfM

HornquistE

1999

The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action.

Eur J Immunol

1774

1784

29. CzerkinskyC

HolmgrenJ

2009

Enteric vaccines for the developing world: a challenge for mucosal immunology.

Mucosal Immunol

284

287

30. HallLJ

ClareS

PickardD

ClarkSO

KellyDL

2009

Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein.

Vaccine

6894

6904

31. CasiniE

1972

[Bacterial vaccines for oral administration and local mechanisms of immunity].

Ann Sclavo

547

553

32. LiangS

HosurKB

NawarHF

RussellMW

ConnellTD

2009

In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli.

Vaccine

4302

4308

33. BoyerJD

RobinsonTM

MaciagPC

PengX

JohnsonRS

2005

DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.

Virology

333

101

34. PerdigonG

AlvarezS

Nader de MaciasME

Pesce de Ruiz HolgadoAA

1988

[Adjuvant activity of lactic bacteria: perspectives for its use in oral vaccines].

Rev Argent Microbiol

141

146

35. PouwelsPH

LeerRJ

ShawM

Heijne den Bak-GlashouwerMJ

TielenFD

1998

Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes.

Int J Food Microbiol

155

167

36. WellsJM

MercenierA

2008

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.

Nat Rev Microbiol

349

362

37. TuckerSN

TingleyDW

ScallanCD

2008

Oral adenoviral-based vaccines: historical perspective and future opportunity.

Expert Rev Vaccines

38. MesteckyJ

NguyenH

CzerkinskyC

KiyonoH

2008

Oral immunization: an update.

Curr Opin Gastroenterol

713

719

39. FuJ

BianG

ZhaoB

DongZ

SunX

2009

Enhancing efficacy and mucosa-tropic distribution of an oral HIV-PsV DNA vaccine in animal models.

J Drug Target

803

812

40. NingJF

ZhuW

XuJP

ZhengCY

MengXL

2009

Oral delivery of DNA vaccine encoding VP28 against white spot syndrome virus in crayfish by attenuated Salmonella typhimurium.

Vaccine

1127

1135

41. CazorlaSI

BeckerPD

FrankFM

EbensenT

SartoriMJ

2008

Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Infect Immun

324

333

42. KindrachukJ

PotterJ

WilsonHL

GriebelP

BabiukLA

2008

Activation and regulation of toll-like receptor 9: CpGs and beyond.

Mini Rev Med Chem

590

600

43. ForsmanA

UshameckisD

BindraA

YunZ

BlombergJ

2003

Uptake of amplifiable fragments of retrotransposon DNA from the human alimentary tract.

Mol Genet Genomics

270

362

368

44. Van KaerL

Ashton-RickardtPG

EichelbergerM

GaczynskaM

NagashimaK

1994

Altered peptidase and viral-specific T cell response in LMP2 mutant mice.

Immunity

533

541

45. ToesRE

NussbaumAK

DegermannS

SchirleM

EmmerichNP

2001

Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products.

J Exp Med

194

46. YorkIA

GoldbergAL

MoXY

RockKL

1999

Proteolysis and class I major histocompatibility complex antigen presentation.

Immunol Rev

172

47. MoXY

CascioP

LemeriseK

GoldbergAL

RockK

1999

Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides.

J Immunol

163

5851

5859

48. AziziA

Diaz-MitomaF

2007

Viral peptide immunogens: current challenges and opportunities.

J Pept Sci

776

786

49. DuesbergU

von demBA

KirschningC

MiyakeK

SauerbruchT

2002

Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV) —core protein is mediated by toll like receptors (TLRs) 2 and 4.

Immunol Lett

50. YamashitaY

MaedaY

TakeshitaF

BrennanPJ

MakinoM

2004

Role of the polypeptide region of a 33 kDa mycobacterial lipoprotein for efficient IL-12 production.

Cell Immunol

229

51. SchroderNW

HeineH

AlexanderC

ManukyanM

EckertJ

2004

Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses.

J Immunol

173

2683

2691

52. JacksonDC

LauYF

LeT

SuhrbierA

DeliyannisG

2004

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

Proc Natl Acad Sci U S A

101

15440

15445

53. VossS

UlmerAJ

JungG

WiesmullerKH

BrockR

2007

The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers.

Eur J Immunol

3489

3498

54. SumikawaY

AsadaH

HoshinoK

AzukizawaH

KatayamaI

2006

Induction of beta-defensin 3 in keratinocytes stimulated by bacterial lipopeptides through toll-like receptor 2.

Microbes Infect

1513

1521

55. SirskyjD

Diaz-MitomaF

GolshaniA

KumarA

AziziA

2010

Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses.

Immunol Cell Biol

E-pub ahead of print. 11 May 2010

56. AziziA

AndersonDE

TorresJV

OgrelA

GhorbaniM

2008

Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques.

J Immunol

180

2174

2186

57. LambertJS

KeeferM

MulliganMJ

SchwartzD

MesteckyJ

2001

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.

Vaccine

3033

3042

58. TacketCO

2009

Plant-based oral vaccines: results of human trials.

Curr Top Microbiol Immunol

332

103

117

59. StreatfieldSJ

2005

Delivery of plant-derived vaccines.

Expert Opin Drug Deliv

719

728

60. StreatfieldSJ

2005

Plant-based vaccines for animal health.

Rev Sci Tech

189

199

61. HammondRW

NemchinovLG

2009

Plant production of veterinary vaccines and therapeutics.

Curr Top Microbiol Immunol

332

102

62. WalmsleyAM

ArntzenCJ

2000

Plants for delivery of edible vaccines.

Curr Opin Biotechnol

126

129

63. HaqTA

MasonHS

ClementsJD

ArntzenCJ

1995

Oral immunization with a recombinant bacterial antigen produced in transgenic plants.

Science

268

714

716

64. NochiT

TakagiH

YukiY

YangL

MasumuraT

2007

Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination.

Proc Natl Acad Sci U S A

104

10986

10991

65. NochiT

YukiY

KatakaiY

ShibataH

TokuharaD

2009

A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity.

J Immunol

183

6538

6544

66. AminM

JaafariMR

TafaghodiM

2009

Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits.

Colloids Surf B Biointerfaces

225

229

67. BorgesO

TavaresJ

deSA

BorchardG

JungingerHE

Cordeiro-da-SilvaA

2007

Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.

Eur J Pharm Sci

278

290

68. KatzDE

DeLorimierAJ

WolfMK

HallER

CasselsFJ

2003

Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.

Vaccine

341

346

69. FreyA

GiannascaKT

WeltzinR

GiannascaPJ

ReggioH

1996

Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting.

J Exp Med

184

1045

1059

70. MannJF

ShakirE

CarterKC

MullenAB

AlexanderJ

2009

Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection.

Vaccine

3643

3649

71. OwenRL

JonesAL

1974

Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles.

Gastroenterology

189

203

72. HathawayLJ

KraehenbuhlJP

2000

The role of M cells in mucosal immunity.

Cell Mol Life Sci

323

332

73. GebertA

GokeM

RothkotterHJ

DietrichCF

2000

[The mechanisms of antigen uptake in the small and large intestines: the roll of the M cells for the initiation of immune responses].

Z Gastroenterol

855

872

74. KuhnEM

KaupFJ

1996

Morphological characteristics of the ileal Peyer's patches in the rhesus macaque: a histological and ultrastructural study.

Anat Histol Embryol

75. ClarkMA

HirstBH

JepsonMA

1998

M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells.

Infect Immun

1237

1243

76. GebertA

PabstR

1999

M cells at locations outside the gut.

Semin Immunol

165

170

77. GebertA

FassbenderS

WernerK

WeissferdtA

1999

The development of M cells in Peyer's patches is restricted to specialized dome-associated crypts.

Am J Pathol

154

1573

1582

78. HolmgrenJ

CzerkinskyC

2005

Mucosal immunity and vaccines.

Nat Med

S45

S53

79. YukiY

KiyonoH

2009

Mucosal vaccines: novel advances in technology and delivery.

Expert Rev Vaccines

1083

1097

80. BraydenDJ

JepsonMA

BairdAW

2005

Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting.

Drug Discov Today

1145

1157

81. KuoleeR

ChenW

2008

M cell-targeted delivery of vaccines and therapeutics.

Expert Opin Drug Deliv

693

702

82. MeynellHM

ThomasNW

JamesPS

HollandJ

TaussigMJ

1999

Up-regulation of microsphere transport across the follicle-associated epithelium of Peyer's patch by exposure to Streptococcus pneumoniae R36a.

FASEB J

611

619

83. TyrerP

RuthFA

KydJ

HarveyM

SizerP

2002

Validation and quantitation of an in vitro M-cell model.

Biochem Biophys Res Commun

299

377

383

84. MannJF

FerroVA

MullenAB

TetleyL

MullenM

2004

Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin.

Vaccine

2425

2429

85. ChouMY

HartvigsenK

HansenLF

FogelstrandL

ShawPX

2008

Oxidation-specific epitopes are important targets of innate immunity.

J Intern Med

263

479

488

86. ScibelliA

MatteoliG

RopertoS

AlimentiE

DipinetoL

2005

Flavoridin inhibits Yersinia enterocolitica uptake into fibronectin-adherent HeLa cells.

FEMS Microbiol Lett

247

87. SaltmanLH

LuY

ZahariasEM

IsbergRR

1996

A region of the Yersinia pseudotuberculosis invasin protein that contributes to high affinity binding to integrin receptors.

J Biol Chem

271

23438

23444

88. SinhaB

FrancoisPP

NusseO

FotiM

HartfordOM

1999

Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1.

Cell Microbiol

101

117

89. JangMH

KweonMN

IwataniK

YamamotoM

TeraharaK

2004

Intestinal villous M cells: an antigen entry site in the mucosal epithelium.

Proc Natl Acad Sci U S A

101

6110

6115

90. KozlowskiPA

WilliamsSB

LynchRM

FlaniganTP

PattersonRR

2002

Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.

J Immunol

169

566

574

91. GuptaPN

KhatriK

GoyalAK

MishraN

VyasSP

2007

M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B.

J Drug Target

701

713

92. LavelleEC

GrantG

PusztaiA

PfullerU

O'HaganDT

2000

Mucosal immunogenicity of plant lectins in mice.

Immunology

93. WangX

KochetkovaI

HaddadA

HoytT

HoneDM

2005

Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope.

Vaccine

3836

3842

94. ManochaM

PalPC

ChitralekhaKT

ThomasBE

TripathiV

2005

Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.

Vaccine

5599

5617

95. ChionhYT

WeeJL

EveryAL

NgGZ

SuttonP

2009

M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens.

Infect Immun

2962

2970

96. GiannascaPJ

GiannascaKT

LeichtnerAM

NeutraMR

1999

Human intestinal M cells display the sialyl Lewis A antigen.

Infect Immun

946

953

97. KerneisS

BogdanovaA

KraehenbuhlJP

PringaultE

1997

Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria.

Science

277

949

952

98. GramLK

RistGM

LennernasH

SteffansenB

2009

Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide.

Eur J Pharm Sci

378

386

99. LimJS

NaHS

LeeHC

ChoyHE

ParkSC

2009

Caveolae-mediated entry of Salmonella typhimurium in a human M-cell model.

Biochem Biophys Res Commun

390

1322

1327

100. GullbergE

LeonardM

KarlssonJ

HopkinsAM

BraydenD

2000

Expression of specific markers and particle transport in a new human intestinal M-cell model.

Biochem Biophys Res Commun

279

808

813

101. HaseK

KawanoK

NochiT

PontesGS

FukudaS

2009

Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response.

Nature

462

226

230

102. TeraharaK

YoshidaM

IgarashiO

NochiT

PontesGS

2008

Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells.

J Immunol

180

7840

7846

103. LangermannS

MollbyR

BurleinJE

PalaszynskiSR

AugusteCG

2000

Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.

J Infect Dis

181

774

778

104. PoggioTV

La TorreJL

ScodellerEA

2006

Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge.

Can J Microbiol

1093

1102

105. BouckaertJ

BerglundJ

SchembriM

DeGE

CoolsL

2005

Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.

Mol Microbiol

441